Selling, General, and Administrative Costs: Genmab A/S vs Dr. Reddy's Laboratories Limited

SG&A Expenses: Genmab vs Dr. Reddy's - A Decade of Growth

__timestampDr. Reddy's Laboratories LimitedGenmab A/S
Wednesday, January 1, 20143878300000079529000
Thursday, January 1, 20154258500000091224000
Friday, January 1, 201645702000000102413000
Sunday, January 1, 201746372000000146987000
Monday, January 1, 201846910000000213695000
Tuesday, January 1, 201948890000000342000000
Wednesday, January 1, 202050129000000661000000
Friday, January 1, 2021545590000001283000000
Saturday, January 1, 2022620810000002676000000
Sunday, January 1, 20231059310000003297000000
Monday, January 1, 202477201000000
Loading chart...

Unveiling the hidden dimensions of data

A Comparative Analysis of SG&A Expenses: Genmab A/S vs Dr. Reddy's Laboratories Limited

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Genmab A/S and Dr. Reddy's Laboratories Limited, from 2014 to 2023.

Dr. Reddy's Laboratories, a major player in the global pharmaceutical market, has seen its SG&A expenses grow by approximately 173% over the past decade, peaking in 2023. This reflects their aggressive expansion and marketing strategies. In contrast, Genmab A/S, a biotechnology company, has experienced a more modest increase in SG&A expenses, with a notable rise of over 400% from 2014 to 2023, indicating strategic investments in research and development.

While Dr. Reddy's expenses dwarf those of Genmab, the latter's rapid growth in SG&A spending highlights its commitment to innovation and market presence. The data for 2024 is incomplete, suggesting ongoing developments in both companies' financial strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025